-

Shareholder Alert: Robbins LLP Announces PharmaCielo Ltd. (PCLOF) Sued for Misleading Shareholders

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that a purchaser of PharmaCielo Ltd. (OTC: PCLOF) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between June 21, 2019 and March 2, 2020. PharmaCielo, through its subsidiary, PharmaCielo Colombia Holdings S.A.S., cultivates, processes, produces, and supplies medical-grade cannabis oil extracts and related products in Colombia and internationally.

If you suffered a loss as a result of PharmaCielo's misconduct, click here.

PharmaCielo Ltd. (PCLOF) Accused of Misleading Shareholders

According to the complaint, in September 2019, PharmaCielo issued a press release announcing that it "ha[d] signed a United States sales agreement with an established multi-state distributor, General Extract LLC." Following this announcement, in November 2019, PharmaCielo released its Company's third quarter 2019 financial statements touting that it was "nearing completion of [its] extraction and processing center ("RTC"), which will expand the Company's extraction capacity." While PharmaCielo's November financial statements purported to list all of the Company's related party transactions, on March 2, 2020, Hindenburg Research reported that General Extract LLC was a related party entity with no credible operations run by PharmaCielo's former COO. The report further asserted that PharmaCielo had engaged in misleading business transactions with General Extract and Xphyto Therapeutics, and questioned the delayed development of its processing center and general misinformation regarding its production facilities. Since this news, shares of PharmaCielo have declined 63% per share, currently trading at around $0.51 per share.

PharmaCielo Ltd. (PCLOF) Shareholders Have Legal Options

Contact us to learn more:
Leo Kandinov
(800) 350-6003
lkandinov@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested. Click here to receive free alerts from Stock Watch when companies engage in wrongdoing.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

Robbins LLP

OTC Pink:PCLOF

Release Versions
$Cashtags

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Robbins LLP Urges BBNX Stockholders Who Lost Money Investing in Beta Bionics, Inc. to Contact the Firm for Information About Leading the Class Action

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Beta Bionics, Inc. (NASDAQ: BBNX) common stock between July 30, 2025 and February 24, 2026, inclusive (the "Class Period"). Beta Bionics is a commercial-stage medical device company that offers an automated insulin delivery system for the treatment of diabetes, known as the iLet Bionic Pancreas insulin pump (...

Robbins LLP Urges HIMS Stockholders Who Lost Money Investing in Hims & Hers Health, Inc. to Contact the Firm for Information About Leading the Class Action

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Hims & Hers Health, Inc. (NYSE: HIMS) securities between August 4, 2025 and July 29, 2026, inclusive (the "Class Period"). Hims operates a health and wellness platform that connects consumers to licensed healthcare professionals.The complaint alleges that Hims & Hers shared customers' protected health...

Robbins LLP Urges UNCY Stockholders Who Lost Money Investing in Unicycive Therapeutics, Inc. to Contact the Firm for Information About Leading the Class Action

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of persons and entities who purchased or otherwise acquired Unicycive Therapeutics, Inc. (NASDAQ: UNCY) securities between December 29, 2025 and June 29, 2026. Unicycive is a clinical-stage biotechnology company that identifies, develops, and commercializes therapies for the treatment of kidney diseases.The complaint alleges that Unicycive failed to properly inspect its t...
Back to Newsroom